Drugs / GC101 TIL
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07294872 | May → Sep 2026 expected | cancer | Shanghai Juncell Therapeutics | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06473961 | Oct 2024 → Jan 2026 overdue | non-small cell lung carcinoma | Shanghai Juncell Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT05417750 | Oct 2022 → Apr 2025 | neoplasm | Shanghai Juncell Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06120712 | Nov 2023 → Nov 2024 | melanoma | Shanghai Juncell Therapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06703398 | Dec 2024 → Jul 2026 overdue | melanoma | Shanghai Juncell Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GC101 TIL | “An Open, Single-armed, Phase Ib Study to Evaluate the Safety and Efficacy Using Autologous Tumor Infiltrating Lymphocytes Injection (GC101 TIL) in Patients With Non-Small Cell...” NCT06473961 ↗5“A tumor sample is resected from each participant and cultured ex vivo to expand the population of autologous tumor infiltrating lymphocytes injection (GC101 TIL).” NCT05417750 ↗ “Autologous Tumor Infiltrating Lymphocytes Injection (GC101 TIL)” NCT07294872 ↗ |
| Modality | Cell therapy | “cultured ex vivo to expand the population of autologous tumor infiltrating lymphocytes injection (GC101 TIL)” NCT05417750 ↗ |
| Route | Intravenous | “infused i.v. into the patient” NCT06120712 ↗ |